Point of Care Diagnostics Market

Point of Care Diagnostics Market Size, Share & Trends by Product (Glucose, HIV, Hep C, HPV, Hematology, Pregnancy), Platform (Microfluidic, Dipstick, RT-PCR, INAAT), Sample (Blood, Urine), Purchase (OTC, Rx), End User (Pharmacy, Hospitals, Home Care) & Region - Global Forecast to 2028

Report Code: MD 2702 Feb, 2024, by marketsandmarkets.com

Point of Care Diagnostics Market Size, Share & Trends

The size of global point of care diagnostics market in terms of revenue was estimated to be worth $49.7 billion in 2023 and is poised to reach $77.8 billion by 2028, growing at a CAGR of 9.4% from 2023 to 2028. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.

Point-of-care diagnostics devices provide quick results and help in making better treatment decisions. The key factors driving market growth include the rising incidence of infectious diseases such as influenza, HIV, tuberculosis, moreover, favourable government policies promoting the adoption of POC testing, rising CLIA-waived point of care tests, and shift towards healthcare decentralization are some of the major factors contributing towards the growth of market during the forecast period. However, the rising pricing pressure on these devices due to reimbursement cuts, and the stringent regulatory approval processes for commercializing POC products is expected to restrain market growth during the forecast period.

Point of Care Diagnostics Market Trends

Point-of-Care Diagnostics Market

To know about the assumptions considered for the study, Request for Free Sample Report

Point-of-Care Diagnostics Market

e- Estimated; p- Projected

Point of care Diagnostics Market Dynamics

Driver: Increasing prevalence of infectious diseases globally

POC tests can primarily improve the management of infectious diseases, especially in emerging markets and resource limited settings. According to UNAIDS, approximately 39 million people were suffering from HIV-AIDS globally as of 2022, and an estimated 1.3 million individuals acquired HIV.

In 2022, Tuberculosis ranked as the second leading cause of death globally among single infectious agents following COVID-19. Globally, the newly diagnosed tuberculosis cases reached 7.5 million in 2022 (Source: WHO Global Tuberculosis Report 2023). Point-of-care tests with high sensitivity and specificity enable the rapid diagnosis of infectious diseases, initiating prompt treatment further enhancing patient outcome. The global rise in prevalence of infectious diseases such as malaria, tuberculosis, HIV are likely to boost the demand for point-of-care diagnostics

Restraint: Pricing pressure on PoC Manufacturers

Intense competition in the POC testing market can lead to pricing pressure, Moreover, decrease in reimbursement rates for POC tests from government payers, private insurers, or healthcare reimbursement programs are driving down profit margins for manufacturer significantly impacting the growth of point of care diagnostics market. Healthcare facilities, especially those in areas with limited resources or financial constraints, may have constrained budgets for investing in point-of-care testing equipment and materials, limiting the adoption of point of care testing.

Opportunity: High growth potential of emerging markets

Emerging markets such as China, India, Brazil, and Mexico are expected to offer significant growth opportunities for players operating in the POC diagnostics market. This is primarily due to the high and growing prevalence of infectious and lifestyle diseases in these countries. To meet the increasing demand for POC diagnostics in emerging markets, manufacturers focus on acquiring or entering into agreements and partnerships with regional/domestic players for product distribution and manufacturing. Regulatory policies in the Asia Pacific region are flexible and have less stringent regulations than established markets in North America and Europe. The saturation of mature markets will further compel manufacturers and leading POC testing companies to shift their focus to emerging markets

Challenge: Inadequate standardization with centralized lab methods

POC test results lack alignment with central lab methods due to many pre- and post-analytical errors. Pre-analytical errors for POC testing include unsuitable indications for the performance of the test, inappropriate sampling times and techniques, lack of information about patient conditions, and other factors such as fasting before functional tests or variations in posture/position during similar tests. On the other hand, post-analytical errors include inadequate technical validation, false assignment of results, and errors in data storage.

POC testing is often conducted in emergencies to facilitate clinical decision-making. In several cases, these tests are conducted by nurses or clinical team members, not physicians. These issues can potentially lead to erroneous diagnoses and affect the quality of patient care. Considering such issues, patients & doctors can decide not to opt for POC testing. This is one of the critical challenges to the higher acceptance of POC testing.

Point of care Diagnostics Market Ecosystem

Point-of-Care Diagnostics Market Ecosystem

The Glucose Monitoring Product segment to hold significant share of the global point of care diagnostics industry, by product type, in 2022

Based on the product, point of care diagnostics market is segmented into glucose monitoring products, cardiometabolic monitoring products, COVID-19 testing products, infectious disease testing products, coagulation monitoring products, pregnancy & fertility testing products, hematology testing products, cancer marker testing products, fecal occult testing products, urinalysis testing products, drug-of-abuse testing products, thyroid-stimulating hormone (TSH) testing products, cholesterol testing products, and other products. In 2022, the glucose monitoring testing products segment accounted for the second largest share of the market. The significant rise in the diabetes cases globally, widespread adoption of glucose monitoring kits, and greater awareness of the diabetes care are expected to propel the growth of the segment

By platform, the lateral flow assay segment held the largest share of point of care diagnostics industry

Based on platform, the point of care diagnostics market is segmented into lateral flow assays, immunoassays, microfluidics, dipsticks, and molecular diagnostics. The lateral flow assays segment accounted for the largest share of the market in 2022. Lateral flow assay is more affordable compared to traditional laboratory testing methods, moreover the ease of conducting lateral flow assay makes this technology well suited for healthcare settings with limited resources, enabling rapid testing for various conditions.

By End User, home care settings and self testing of the point of care diagnostics industry to grow at a significant rate from 2023-2028

Based on end user, home care setting and self-testing segment is expected to grow at a significant rate owing to growing awareness about home care, increasing availability of user-friendly and advanced POC diagnostic products, including blood glucose, cholesterol, and pregnancy. Additionally, the COVID 19 pandemic has accelerated the adoption of home care self-testing products, particularly for diagnostic testing and monitoring of infectious diseases. Along with this the rising partnerships, and collaborations among various players to develop novel rapid testing products for home use are likely to contribute towards the rapid growth of the segment

Point-of-Care Diagnostics Market by Region

To know about the assumptions considered for the study, download the pdf brochure

North America to account for the largest share of point of care diagnostics industry during the forecast period.

North America is the expected to be the largest regional market for point of care diagnostics during the forecast period. The presence of a well-established healthcare system, rapid adoption of advanced point of care testing products, increase in the availability of medical reimbursement, favourable government support for the novel product development, and higher user awareness about the presence of point of care testing products are anticipated to support the market growth in the region

As of 2022, Prominent players in the point of care diagnostics market include Abbott Laboratories (US), F. Hoffman-La Roche Ltd. (Switzerland), BD (US), Danaher Corporation (US), Siemens Healthineers (Germany), QuidelOrtho Corporation (US), Chembio Diagnostics, Inc. (US), EKF Diagnostics Holdings plc (UK), among others

Scope of the Point of Care Diagnostics Industry

Report Metric

Details

Market Revenue Size in 2023

$49.7 billion

Projected Revenue Size by 2028

$77.8 billion

Industry Growth Rate

Poised to Grow at a CAGR of 9.4%

Market Driver

Increasing prevalence of infectious diseases globally

Market Opportunity

High growth potential of emerging markets

This research report categorizes the point of care diagnostics market to forecast revenue and analyze trends in each of the following submarkets:

By Product
  • COVID-19 test products
  • Glucose Monitoring Products
    • Strips
    • Meters
    • Lancets & Lancing Devices
  • Cardiometabolic Monitoring Products
    • Point-of-care and rapid diagnostics Products
    • Blood Gas/Electrolyte Testing Products
    • HbA1c Testing Products
  • Infectious Disease Testing Products
    • Influenza Testing Products
    • HIV Testing Products
    • Hepatitis C Testing Products
    • Influenza Testing Products
      • Sexually Transmitted Disease Testing Products
        • Syphilis Testing Products
        • Human Papillomavirus (HPV) Testing Products
        • Chlamydia Trachomatis Testing Products
        • Herpes simplex virus (HSV) Testing Products
      • Healthcare-associated Infection Testing Products
      • Respiratory Infection Testing Products
      • Tuberculosis (TB) Testing Products
      • Clostridium Difficile Infection (CDI) Testing Products
      • Tropical Disease Testing Products
      • Other Infectious Disease Testing Products
  • Coagulation Monitoring Products
    • PT/INR Testing
    • ACT/APTT
  • Pregnancy & Fertility Testing Products
    • Pregnancy Testing Products
    • Fertility Testing Products
  • Tumor/Cancer Marker Testing Products
  • Urinalysis Testing Products
  • Cholesterol Testing Products
  • Hematology Testing Products
  • Thyroid Stimulating Hormone (TSH) Testing Products
  • Drugs-of-abuse Testing Products
  • Fecal Occult Testing Products
  • Other POC Products

Note* Other PoC products include multi-assay testing, disease-resistant bacteria testing, vitamin assay testing

By Platform
  • Lateral Flow Assays
  • Dipsticks
  • Microfluidics
  • Molecular Diagnostics
    • Polymerase Chain Reaction (PCR)
    • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Other Molecular Diagnostic Technologies
  • Immunoassays
By Mode of Purchase
  • Prescription-based Products
  • OTC Products
By Sample
  • Blood Sample
  • Urine Sample
  • Nasal and Oropharyngeal Swabs Sample
  • Other Samples

Note*Other samples include saliva, sputum, stool, and urethral/genital swabs.

By End User
  • Clinical Laboratories
  • Ambulatory Care Facilities and Physician Offices
  • Pharmacies, retail clinics, & E-comm. Platforms
  • Hospitals, Critical Care Centers, Urgent care centers
  • Home Care & Self Testing
  • Other End Users

Note*Other end users includes rehabilitation centers, sports centers, nursing homes, research institutes, and blood banks.

By Region
  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • RoAPAC
  • Latin America
    • Brazil
    • Mexico
    • RoLATAM
  • Middle East & Africa
    • GCC Countries
    • Rest of Middle East & Africa

Recent Developments of Point of Care Diagnostics Industry:

  • In May 2023, bioMérieux received the US FDA CLIA-waiver for the BIOFIRE SPOTFIRE Respiratory (R) Panel Mini,a second multiplex PCR-based test cleared for use on the BIOFIRE SPOTFIRE System
  • In August 2023, BD received the US FDA approval for its BD Respiratory Viral Panel (RVP) for BD MAX System, a single molecular diagnostic combination test that identifies & distinguishes SARS-CoV-2, influenza A, influenza B, and Respiratory Syncytial Virus (RSV) in ~ 2 hours.
  • In December 2023, Thermo Fisher Scientific Inc. and Project HOPE, a leading global health and humanitarian organization, partnered to expand the accessibility of HIV testing services offered by Thermo Fisher among HIV Positive Youth in Sub-Saharan Africa.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 34)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 STUDY SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 REGIONS COVERED
           1.3.3 YEARS CONSIDERED
           1.3.4 CURRENCY CONSIDERED
    1.4 KEY STAKEHOLDERS 
    1.5 SUMMARY OF CHANGES 
    1.6 RECESSION IMPACT 
 
2 RESEARCH METHODOLOGY (Page No. - 41)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY RESEARCH
           2.1.2 PRIMARY RESEARCH
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
                                FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                                FIGURE 3 BREAKDOWN OF PRIMARIES
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
           2.2.1 VENDOR REVENUE MAPPING-BASED MARKET ESTIMATION
           2.2.2 END-USER ASSESSMENT-BASED MARKET ESTIMATION
                    FIGURE 5 POINT OF CARE DIAGNOSTICS MARKET: MARKET SIZE ESTIMATION METHODOLOGY
           2.2.3 PRIMARY RESEARCH VALIDATION
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 6 DATA TRIANGULATION METHODOLOGY
    2.4 RESEARCH LIMITATIONS 
    2.5 RECESSION IMPACT ANALYSIS 
          TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
 
3 EXECUTIVE SUMMARY (Page No. - 52)
    FIGURE 7 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
    FIGURE 8 POINT OF CARE DIAGNOSTICS INDUSTRY, BY PLATFORM, 2023 VS. 2028 (USD MILLION)
    FIGURE 9 MARKET, BY MODE OF PURCHASE, 2023 VS. 2028 (USD MILLION)
    FIGURE 10 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 11 GEOGRAPHIC SNAPSHOT OF MARKET
 
4 PREMIUM INSIGHTS (Page No. - 56)
    4.1 POINT OF CARE DIAGNOSTICS MARKET OVERVIEW 
          FIGURE 12 INCREASING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
    4.2 POINT OF CARE DIAGNOSTICS INDUSTRY, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 
          FIGURE 13 INFECTIOUS DISEASE TESTING PRODUCTS TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
    4.3 MARKET, BY MODE OF PURCHASE (2022) 
          FIGURE 14 OTC TESTING PRODUCTS ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    4.4 MARKET, BY PLATFORM, 2023 VS. 2028 
          FIGURE 15 LATERAL FLOW ASSAYS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
    4.5 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 16 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 60)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 17 POINT OF CARE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Rising incidence of infectious diseases
                                FIGURE 18 REGIONAL INCIDENCE OF HIV (2022)
                    5.2.1.2 Increasing prevalence of target conditions
                    5.2.1.3 Favorable government initiatives for POC testing
                    5.2.1.4 Rising number of CLIA-waived POC tests
                                TABLE 2 RECENT WAIVERS FOR PRODUCTS
           5.2.2 RESTRAINTS
                    5.2.2.1 Pricing pressure on POC manufacturers
                    5.2.2.2 Stringent regulatory approval process for product commercialization
           5.2.3 OPPORTUNITIES
                    5.2.3.1 High growth potential of emerging markets
                    5.2.3.2 Decentralization of healthcare
                    5.2.3.3 Innovative product development
           5.2.4 CHALLENGES
                    5.2.4.1 Inadequate standardization with centralized lab methods
                    5.2.4.2 Limited awareness in emerging markets
                    5.2.4.3 Premium pricing of novel platforms
    5.3 TECHNOLOGY ANALYSIS 
           5.3.1 POC TESTS WITH MULTIPLEXING CAPABILITIES
           5.3.2 STROKE/CARDIAC MARKERS
           5.3.3 THYROID TESTING
           5.3.4 DNA TESTING
           5.3.5 ENDOCRINE TESTING
           5.3.6 RESPIRATORY DIAGNOSTICS
    5.4 REGULATORY LANDSCAPE 
          TABLE 3 REGULATORY BODIES AND GOVERNMENT AGENCIES
           5.4.1 KEY REGULATORY GUIDELINES
                    5.4.1.1 US
                                FIGURE 19 US: REGULATORY PROCESS FOR IVD DEVICES
                    5.4.1.2 Canada
                                FIGURE 20 CANADA: REGULATORY PROCESS FOR IVD DEVICES
                    5.4.1.3 Europe
                                FIGURE 21 EUROPE: REGULATORY PROCESS FOR IVD DEVICES
                    5.4.1.4 Japan
                                FIGURE 22 JAPAN: REGULATORY PROCESS FOR IVD DEVICES
                    5.4.1.5 China
                                TABLE 4 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
                    5.4.1.6 India
                                FIGURE 23 INDIA: REGULATORY PROCESS FOR IVD DEVICES
                    5.4.1.7 Brazil
                                FIGURE 24 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
    5.5 VALUE CHAIN ANALYSIS 
          FIGURE 25 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING REGULATION & DISTRIBUTION STAGES
    5.6 SUPPLY CHAIN ANALYSIS 
           5.6.1 PROMINENT COMPANIES
           5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES
           5.6.3 END USERS
                    FIGURE 26 SUPPLY CHAIN ANALYSIS
           5.6.4 PRICING ANALYSIS
                    TABLE 5 AVERAGE SELLING PRICE OF LEADING PRODUCTS, BY KEY PLAYER (USD)
                    FIGURE 27 AVERAGE SELLING PRICE OF TOP 2 LEADING PRODUCTS, BY KEY PLAYER
                    5.6.4.1 Average selling price trend
                                TABLE 6 AVERAGE PRICE OF GLUCOSE MONITORING & CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022 (USD)
                                TABLE 7 AVERAGE PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022 (USD)
                                TABLE 8 AVERAGE PRICE OF OTHER POINT-OF-CARE TESTING PRODUCTS, BY COUNTRY, 2022 (USD)
    5.7 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 9 POINT OF CARE DIAGNOSTICS INDUSTRY: PORTER’S FIVE FORCES ANALYSIS
           5.7.1 BARGAINING POWER OF BUYERS
           5.7.2 BARGAINING POWER OF SUPPLIERS
           5.7.3 THREAT OF NEW ENTRANTS
           5.7.4 THREAT OF SUBSTITUTES
           5.7.5 INTENSITY OF COMPETITIVE RIVALRY
    5.8 TRADE DATA 
          TABLE 10 IMPORT DATA FOR MALARIA DIAGNOSTICS KITS (HS CODE 300211), BY COUNTRY, 2018–2021 (USD MILLION)
          TABLE 11 EXPORT DATA FOR MALARIA DIAGNOSTICS KITS (HS CODE 300211), BY COUNTRY, 2018–2021 (USD MILLION)
    5.9 REIMBURSEMENT SCENARIO 
          TABLE 12 KEY MEDICARE CLINICAL LAB FEE SCHEDULE (CLFS) CODES FOR COVID-19 TESTING
          TABLE 13 MEDICARE HCPCS CODES FOR HIV TESTING
    5.10 PATENT ANALYSIS 
          FIGURE 28 TOP 10 PATENT OWNERS FOR POINT-OF-CARE DIAGNOSTICS (JANUARY 2012–DECEMBER 2023)
           5.10.1 ECOSYSTEM/MARKET MAP
                     FIGURE 29 ANALYSIS OF PARENT MARKET: IN VITRO DIAGNOSTICS MARKET
           5.10.2 KEY CONFERENCES & EVENTS
                     TABLE 14 MARKET: LIST OF KEY CONFERENCES & EVENTS (2023−2024)
    5.11 CASE STUDY ANALYSIS 
           5.11.1 DEVELOPMENT OF HIGH-SENSITIVITY TROPONIN I
                     TABLE 15 CASE 1: DIAGNOSING LOWER LEVELS OF TROPONIN IN CARDIAC PATIENTS
    5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 
          FIGURE 30 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX
    5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF POINT-OF-CARE TESTING KITS & INSTRUMENTS
                     TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR POINT-OF-CARE TESTING KITS AND INSTRUMENTS (%)
    5.14 BUYING CRITERIA 
           FIGURE 32 KEY BUYING CRITERIA FOR POINT-OF-CARE TESTING KITS & INSTRUMENTS
           TABLE 17 KEY BUYING CRITERIA FOR POC PRODUCTS
 
6 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE (Page No. - 90)
    6.1 INTRODUCTION 
          TABLE 18 POINT OF CARE DIAGNOSTICS INDUSTRY, BY MODE OF PURCHASE, 2021–2028 (USD MILLION)
    6.2 OTC TESTING PRODUCTS 
           6.2.1 GROWING PATIENT PREFERENCE FOR REMOTE HEALTHCARE TO PROPEL MARKET
                    TABLE 19 OTC TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
    6.3 PRESCRIPTION-BASED TESTING PRODUCTS 
           6.3.1 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET
                    TABLE 20 PRESCRIPTION-BASED TESTING PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION)
 
7 POINT OF CARE DIAGNOSTICS MARKET, BY PLATFORM (Page No. - 94)
    7.1 INTRODUCTION 
          TABLE 21 POINT OF CARE DIAGNOSTICS INDUSTRY, BY PLATFORM, 2021–2028 (USD MILLION)
    7.2 LATERAL FLOW ASSAYS 
           7.2.1 RISING ADOPTION OF TESTING PRODUCTS IN HOME CARE SETTINGS TO DRIVE MARKET
                    TABLE 22 MARKET FOR LATERAL FLOW ASSAYS, BY REGION, 2021–2028 (USD MILLION)
    7.3 IMMUNOASSAYS 
           7.3.1 UTILIZATION IN INFECTIOUS DISEASE TESTING TO SUPPORT MARKET GROWTH
                    TABLE 23 MARKET FOR IMMUNOASSAYS, BY REGION, 2021–2028 (USD MILLION)
    7.4 MICROFLUIDICS 
           7.4.1 GROWING TREND OF MINIATURIZATION AND RISING TECHNOLOGICAL ADVANCEMENTS TO PROPEL MARKET
                    TABLE 24 MARKET FOR MICROFLUIDICS, BY REGION, 2021–2028 (USD MILLION)
    7.5 DIPSTICKS 
           7.5.1 QUALITATIVE ANALYSIS OF MEDICAL CONDITIONS TO SUPPORT MARKET GROWTH
                    TABLE 25 MARKET FOR DIPSTICKS, BY REGION, 2021–2028 (USD MILLION)
    7.6 MOLECULAR DIAGNOSTICS 
          TABLE 26 MARKET FOR MOLECULAR DIAGNOSTICS, BY TECHNOLOGY, 2021–2028 (USD MILLION)
          TABLE 27 MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION)
           7.6.1 RT-PCR
                    7.6.1.1 Rising cases of COVID-19 to boost demand
                                TABLE 28 MARKET FOR RT-PCR, BY REGION, 2021–2028 (USD MILLION)
           7.6.2 INAAT
                    7.6.2.1 Cost benefits of INAAT to propel segment growth
                                TABLE 29 MARKET FOR INAAT, BY REGION, 2021–2028 (USD MILLION)
           7.6.3 OTHER TECHNOLOGIES
                    TABLE 30 MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION)
 
8 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE (Page No. - 103)
    8.1 INTRODUCTION 
          TABLE 31 POINT OF CARE DIAGNOSTICS INDUSTRY, BY SAMPLE, 2021–2028 (USD MILLION)
    8.2 BLOOD SAMPLES 
           8.2.1 HIGH UTILIZATION IN DISEASE DETECTION TO DRIVE MARKET
                    TABLE 32 MARKET FOR BLOOD SAMPLES, BY REGION, 2021–2028 (USD MILLION)
    8.3 URINE SAMPLES 
           8.3.1 INCREASING PREVALENCE OF KIDNEY DISORDERS AND WIDE RANGE OF DIAGNOSTIC TARGETS TO BOOST DEMAND
                    TABLE 33 MARKET FOR URINE SAMPLES, BY REGION, 2021–2028 (USD MILLION)
    8.4 NASAL & OROPHARYNGEAL SWABS 
           8.4.1 RISING INCIDENCE OF RESPIRATORY INFECTIONS TO PROPEL MARKET
                    TABLE 34 MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY REGION, 2021–2028 (USD MILLION)
    8.5 OTHER SAMPLES 
          TABLE 35 MARKET FOR OTHER SAMPLES, BY REGION, 2021–2028 (USD MILLION)
 
9 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT (Page No. - 107)
    9.1 INTRODUCTION 
          TABLE 36 POINT OF CARE DIAGNOSTICS INDUSTRY, BY PRODUCT, 2021–2028 (USD MILLION)
    9.2 GLUCOSE MONITORING PRODUCTS 
          TABLE 37 MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 38 MARKET FOR GLUCOSE MONITORING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
           9.2.1 STRIPS
                    9.2.1.1 Ability to provide single-use measurement testing to drive market
                                TABLE 39 GLUCOSE MONITORING STRIPS MARKET, BY REGION, 2021–2028 (USD MILLION)
           9.2.2 METERS
                    9.2.2.1 Ability to adjust therapeutic regimens daily to support market growth
                                TABLE 40 GLUCOSE MONITORING METERS MARKET, BY REGION, 2021–2028 (USD MILLION)
           9.2.3 LANCETS & LANCING DEVICES
                    9.2.3.1 Provision of multiple depth penetration settings to boost demand
                                TABLE 41 GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
    9.3 COVID-19 TESTING PRODUCTS 
           9.3.1 RISING UPTAKE OF RT-PCR RAPID TESTS TO BOOST DEMAND
                    TABLE 42 MARKET FOR COVID-19 TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
    9.4 CARDIOMETABOLIC MONITORING PRODUCTS 
          TABLE 43 MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 44 MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
           9.4.1 CARDIAC MARKER TESTING PRODUCTS
                    9.4.1.1 Rising government initiatives for CVD research to drive market
                                TABLE 45 MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
           9.4.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS
                    9.4.2.1 Technological advancements in monitoring products to support market growth
                                TABLE 46 MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
           9.4.3 HBA1C TESTING PRODUCTS
                    9.4.3.1 Favorable clinical outcomes with long-term monitoring to drive market
                                TABLE 47 MARKET FOR HBA1C TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
    9.5 INFECTIOUS DISEASE TESTING PRODUCTS 
          TABLE 48 MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 49 MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
           9.5.1 HIV TESTING PRODUCTS
                    9.5.1.1 Rising prevalence of HIV to drive market
                                TABLE 50 MARKET FOR HIV TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
           9.5.2 RESPIRATORY INFECTION TESTING PRODUCTS
                    9.5.2.1 Rising incidence of respiratory infections to drive market
                                TABLE 51 MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
           9.5.3 HEPATITIS C TESTING PRODUCTS
                    9.5.3.1 Increasing prevalence of viral hepatitis to support market growth
                                TABLE 52 MARKET FOR HEPATITIS C TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
           9.5.4 HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS
                    9.5.4.1 High incidence of UTIs and surgical-site infections to boost demand
                                TABLE 53 MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
           9.5.5 INFLUENZA TESTING PRODUCTS
                    9.5.5.1 Ability to identify A & B viral nucleoprotein antigens to drive market
                                TABLE 54 MARKET FOR INFLUENZA TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
           9.5.6 TROPICAL DISEASE TESTING PRODUCTS
                    9.5.6.1 Rising incidence of malaria and dengue to support market growth
                                TABLE 55 MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
           9.5.7 SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS
                    TABLE 56 MARKET FOR STD TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 57 MARKET FOR STD TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
                    9.5.7.1 Syphilis testing products
                               9.5.7.1.1 Introduction of rapid tests to boost demand
                                              TABLE 58 DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
                    9.5.7.2 Human papillomavirus (HPV) testing products
                               9.5.7.2.1 Rising uptake of HPV diagnostics and RT-PCR to support market growth
                                              TABLE 59 DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
                    9.5.7.3 Chlamydia trachomatis testing products
                               9.5.7.3.1 Growing awareness of STI detection to boost demand
                                              TABLE 60 DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
                    9.5.7.4 Herpes simplex virus (HSV) testing products
                               9.5.7.4.1 Increasing incidence of HSV to support market growth
                                              TABLE 61 DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
           9.5.8 TUBERCULOSIS
                    9.5.8.1 Rising prevalence of TB in underserved areas to support market growth
                                TABLE 62 DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2021–2028 (USD MILLION)
           9.5.9 CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS
                    9.5.9.1 Rising cases among hospitalized patients to boost demand
                                TABLE 63 DIAGNOSTICS MARKET FOR CDI, BY REGION, 2021–2028 (USD MILLION)
           9.5.10 OTHER INFECTIOUS DISEASE TESTING PRODUCTS
                     TABLE 64 POINT OF CARE DIAGNOSTICS INDUSTRY FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
    9.6 COAGULATION MONITORING PRODUCTS 
          TABLE 65 MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 66 MARKET FOR COAGULATION MONITORING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
           9.6.1 PT/INR TESTING PRODUCTS
                    9.6.1.1 Ability to detect blood clots to support market growth
                                TABLE 67 DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
           9.6.2 ACT/APTT TESTING PRODUCTS
                    9.6.2.1 Rising cases of dialysis and ESRD to boost demand
                                TABLE 68 DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
    9.7 PREGNANCY & FERTILITY TESTING PRODUCTS 
          TABLE 69 MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 70 MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
           9.7.1 PREGNANCY TESTING PRODUCTS
                    9.7.1.1 Growing preference for home care testing to drive market
                                TABLE 71 MARKET FOR PREGNANCY TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
           9.7.2 FERTILITY TESTING PRODUCTS
                    9.7.2.1 Growing focus on family planning to boost demand
                                TABLE 72 MARKET FOR FERTILITY TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
    9.8 TUMOR/CANCER MARKER TESTING PRODUCTS 
           9.8.1 INCREASING INCIDENCE OF CANCER AND RISING UPTAKE OF IMMUNOASSAYS TO PROPEL MARKET
                    TABLE 73 MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
    9.9 URINALYSIS TESTING PRODUCTS 
           9.9.1 HIGH INCIDENCE OF RECURRENT UTIS TO DRIVE MARKET
                    TABLE 74 MARKET FOR URINALYSIS TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
    9.10 CHOLESTEROL TESTING PRODUCTS 
           9.10.1 RISING OBESITY LEVELS AND INCIDENCE OF CVD TO BOOST DEMAND
                      TABLE 75 MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
    9.11 HEMATOLOGY TESTING PRODUCTS 
           9.11.1 PREFERENCE FOR LABORATORY-BASED TESTS TO RESTRAIN MARKET
                      TABLE 76 MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY REGION, 2021–2028(USD MILLION)
    9.12 DRUGS-OF-ABUSE TESTING PRODUCTS 
           9.12.1 RISING CONSUMPTION OF ILLICIT DRUGS TO FUEL MARKET
                      TABLE 77 MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
    9.13 THYROID-STIMULATING HORMONE (TSH) TESTING PRODUCTS 
           9.13.1 RISING CASES OF THYROID TO BOOST DEMAND
                      TABLE 78 MARKET FOR TSH TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
    9.14 FECAL OCCULT TESTING PRODUCTS 
           9.14.1 INCREASING AWARENESS ON EARLY DISEASE DETECTION TO SUPPORT MARKET GROWTH
                      TABLE 79 MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
    9.15 OTHER PRODUCTS 
           TABLE 80 MARKET FOR OTHER PRODUCTS, BY REGION, 2021–2028 (USD MILLION)
 
10 POINT OF CARE DIAGNOSTICS MARKET, BY END USER (Page No. - 140)
     10.1 INTRODUCTION 
             TABLE 81 POINT OF CARE DIAGNOSTICS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
     10.2 CLINICAL LABORATORIES 
             10.2.1 IMPROVEMENTS IN AUTOMATED TESTING SERVICES TO BOOST DEMAND
                        TABLE 82 MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
     10.3 AMBULATORY CARE FACILITIES AND PHYSICIANS’ OFFICES 
             10.3.1 RAPID RESULT GENERATION AND AVAILABILITY OF IMMEDIATE PATIENT CARE TO DRIVE MARKET
                        TABLE 83 MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIANS’ OFFICES, BY REGION, 2021–2028 (USD MILLION)
     10.4 PHARMACIES, RETAIL CLINICS, AND E-COMMERCE PLATFORMS 
             10.4.1 ABILITY TO SUPPORT CHRONIC DISEASE MANAGEMENT TO BOOST DEMAND
                        TABLE 84 MARKET FOR PHARMACIES, RETAIL CLINICS, AND E-COMMERCE PLATFORMS, BY REGION, 2021–2028 (USD MILLION)
     10.5 HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS 
             10.5.1 RAPID RESULTS AND END USERS OF POC DIAGNOSTICS
                        TABLE 85 MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY REGION, 2021–2028 (USD MILLION)
     10.6 HOME CARE SETTINGS AND SELF-TESTING 
             10.6.1 GROWING INCLINATION TOWARDS REMOTE-BASED CARE TO DRIVE MARKET
                        TABLE 86 MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY REGION, 2021–2028 (USD MILLION)
     10.7 OTHER END USERS 
             TABLE 87 MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
 
11 POINT OF CARE DIAGNOSTICS MARKET, BY REGION (Page No. - 147)
     11.1 INTRODUCTION 
             TABLE 88 POINT OF CARE DIAGNOSTICS INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
     11.2 NORTH AMERICA 
             11.2.1 NORTH AMERICA: RECESSION IMPACT
                        FIGURE 33 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET SNAPSHOT
                        TABLE 89 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 90 NORTH AMERICA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 91 NORTH AMERICA: MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 92 NORTH AMERICA: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 93 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 94 NORTH AMERICA: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 95 NORTH AMERICA: MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 96 NORTH AMERICA: MARKET, BY PLATFORM, 2021–2028 (USD MILLION)
                        TABLE 97 NORTH AMERICA: MARKET, BY MODE OF PURCHASE, 2021–2028 (USD MILLION)
                        TABLE 98 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
                        TABLE 99 NORTH AMERICA: MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
             11.2.2 US
                        11.2.2.1 Favorable government support and medical reimbursements to boost demand
                                      TABLE 100 US: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             11.2.3 CANADA
                        11.2.3.1 Rising incidence of diabetes and cancer to support market growth
                                      TABLE 101 CANADA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
     11.3 EUROPE 
             11.3.1 EUROPE: RECESSION IMPACT
                        TABLE 102 EUROPE: POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 103 EUROPE: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 104 EUROPE: MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 105 EUROPE: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 106 EUROPE: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 107 EUROPE: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 108 EUROPE: MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 109 EUROPE: MARKET, BY PLATFORM, 2021–2028 (USD MILLION)
                        TABLE 110 EUROPE: MARKET, BY MODE OF PURCHASE, 2021–2028 (USD MILLION)
                        TABLE 111 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
                        TABLE 112 EUROPE: MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
             11.3.2 GERMANY
                        11.3.2.1 Rising demand for innovative technologies to propel market
                                      TABLE 113 GERMANY: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             11.3.3 FRANCE
                        11.3.3.1 Growing public-private collaborations for product development to drive market
                                      TABLE 114 FRANCE: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             11.3.4 UK
                        11.3.4.1 Growing number of accredited diagnostic & hospital laboratories to propel market
                                      TABLE 115 UK: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             11.3.5 ITALY
                        11.3.5.1 Increasing adoption of infectious disease diagnostics to drive market
                                      TABLE 116 ITALY: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             11.3.6 SPAIN
                        11.3.6.1 Rising incidence of chronic diseases to support market growth
                                      TABLE 117 SPAIN: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             11.3.7 REST OF EUROPE
                        TABLE 118 REST OF EUROPE: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
     11.4 ASIA PACIFIC 
             11.4.1 ASIA PACIFIC: RECESSION IMPACT
                        FIGURE 34 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET SNAPSHOT
                        TABLE 119 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 120 ASIA PACIFIC: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 121 ASIA PACIFIC: MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 122 ASIA PACIFIC: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 123 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 124 ASIA PACIFIC: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 125 ASIA PACIFIC: MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 126 ASIA PACIFIC: MARKET, BY PLATFORM, 2021–2028 (USD MILLION)
                        TABLE 127 ASIA PACIFIC: MARKET, BY MODE OF PURCHASE, 2021–2028 (USD MILLION)
                        TABLE 128 ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
                        TABLE 129 ASIA PACIFIC: MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
             11.4.2 JAPAN
                        11.4.2.1 Availability of advanced rapid flu tests to drive market
                                      TABLE 130 JAPAN: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             11.4.3 CHINA
                        11.4.3.1 Rising incidence of infectious diseases to drive market
                                      TABLE 131 CHINA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             11.4.4 INDIA
                        11.4.4.1 High burden of chronic diseases to propel market
                                      TABLE 132 INDIA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             11.4.5 AUSTRALIA
                        11.4.5.1 Increasing research investments for next-gen POC devices to fuel market
                                      TABLE 133 AUSTRALIA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION
             11.4.6 SOUTH KOREA
                        11.4.6.1 Growing awareness about advanced POC devices to boost demand
                                      TABLE 134 SOUTH KOREA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             11.4.7 REST OF ASIA PACIFIC
                        TABLE 135 REST OF ASIA PACIFIC: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
     11.5 LATIN AMERICA 
             11.5.1 LATIN AMERICA: RECESSION IMPACT
                        TABLE 136 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 137 LATIN AMERICA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 138 LATIN AMERICA: MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 139 LATIN AMERICA: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 140 LATIN AMERICA: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 141 LATIN AMERICA: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 142 LATIN AMERICA: MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 143 LATIN AMERICA: MARKET, BY PLATFORM, 2021–2028 (USD MILLION)
                        TABLE 144 LATIN AMERICA: MARKET, BY MODE OF PURCHASE, 2021–2028 (USD MILLION)
                        TABLE 145 LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
                        TABLE 146 LATIN AMERICA: MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
             11.5.2 BRAZIL
                        11.5.2.1 Rising prevalence of diabetes to support market growth
                                      TABLE 147 BRAZIL: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             11.5.3 MEXICO
                        11.5.3.1 Rising incidence of cancer to drive market
                                      TABLE 148 MEXICO: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             11.5.4 REST OF LATIN AMERICA
                        TABLE 149 REST OF LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
     11.6 MIDDLE EAST & AFRICA 
             11.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT
                        TABLE 150 MIDDLE EAST & AFRICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 151 MIDDLE EAST & AFRICA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 152 MIDDLE EAST & AFRICA: MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 153 MIDDLE EAST & AFRICA: MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 154 MIDDLE EAST & AFRICA: MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 155 MIDDLE EAST & AFRICA: MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 156 MIDDLE EAST & AFRICA: MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 157 MIDDLE EAST & AFRICA: MARKET, BY PLATFORM, 2021–2028 (USD MILLION)
                        TABLE 158 MIDDLE EAST & AFRICA: MARKET, BY MODE OF PURCHASE, 2021–2028 (USD MILLION)
                        TABLE 159 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
                        TABLE 160 MIDDLE EAST & AFRICA: MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
                        11.6.1.1 GCC Countries
                                     11.6.1.1.1 Improvements in healthcare infrastructure to drive market
                                                     TABLE 161 GCC COUNTRIES: POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             11.6.2 REST OF MIDDLE EAST & AFRICA
                        TABLE 162 REST OF AFRICA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 163 REST OF MIDDLE EAST & AFRICA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
 
12 COMPETITIVE LANDSCAPE (Page No. - 208)
     12.1 INTRODUCTION 
     12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 
             FIGURE 35 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN POINT-OF-CARE DIAGNOSTICS MARKET
     12.3 REVENUE SHARE ANALYSIS 
             FIGURE 36 REVENUE ANALYSIS OF TOP FIVE PLAYERS IN POINT OF CARE DIAGNOSTICS INDUSTRY (2022)
     12.4 MARKET SHARE ANALYSIS 
             FIGURE 37 POINT OF CARE DIAGNOSTICS INDUSTRY SHARE, BY KEY PLAYER (2022)
     12.5 COMPANY EVALUATION MATRIX 
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
                       FIGURE 38 COMPANY EVALUATION MATRIX
             12.5.5 COMPANY FOOTPRINT
                        12.5.5.1 Product & regional footprint
                                      TABLE 164 OVERALL FOOTPRINT
                                      TABLE 165 PRODUCT FOOTPRINT
                                      TABLE 166 REGIONAL FOOTPRINT
     12.6 START-UP/SME EVALUATION MATRIX 
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 RESPONSIVE COMPANIES
             12.6.3 DYNAMIC COMPANIES
             12.6.4 STARTING BLOCKS
                        FIGURE 39 START-UP/SME EVALUATION MATRIX
             12.6.5 COMPETITIVE BENCHMARKING
                        TABLE 167 POINT OF CARE DIAGNOSTICS INDUSTRY: DETAILED LIST OF KEY START-UPS/SMES
     12.7 COMPETITIVE SCENARIO 
             12.7.1 PRODUCT LAUNCHES & APPROVALS
                        TABLE 168 POINT OF CARE DIAGNOSTICS INDUSTRY: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020–NOVEMBER 2023)
             12.7.2 DEALS
                        TABLE 169 POINT OF CARE DIAGNOSTICS INDUSTRY: DEALS (JANUARY 2020–NOVEMBER 2023)
             12.7.3 OTHER DEVELOPMENTS
                        TABLE 170 POINT OF CARE DIAGNOSTICS INDUSTRY: OTHER DEVELOPMENTS (JANUARY 2020–NOVEMBER 2023)
 
13 COMPANY PROFILES (Page No. - 223)
     13.1 KEY PLAYERS 
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
             13.1.1 ABBOTT LABORATORIES
                        TABLE 171 ABBOTT LABORATORIES: COMPANY OVERVIEW
                        FIGURE 40 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
             13.1.2 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 172 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
                        FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
             13.1.3 SIEMENS HEALTHINEERS
                        TABLE 173 SIEMENS HEALTHINEERS: COMPANY OVERVIEW
                        FIGURE 42 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2023)
             13.1.4 QUIDELORTHO CORPORATION
                        TABLE 174 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
                        FIGURE 43 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)
             13.1.5 DANAHER CORPORATION
                        TABLE 175 DANAHER CORPORATION: COMPANY OVERVIEW
                        FIGURE 44 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
             13.1.6 BECTON, DICKINSON AND COMPANY
                        TABLE 176 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
                        FIGURE 45 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)
             13.1.7 THERMO FISHER SCIENTIFIC INC.
                        TABLE 177 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
                        FIGURE 46 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
                        TABLE 178 PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS
             13.1.8 BIOMÉRIEUX
                        TABLE 179 BIOMÉRIEUX : COMPANY OVERVIEW
                        FIGURE 47 BIOMÉRIEUX : COMPANY SNAPSHOT (2022)
             13.1.9 CHEMBIO DIAGNOSTICS, INC.
                        TABLE 180 CHEMBIO DIAGNOSTICS, INC.: COMPANY OVERVIEW
                        FIGURE 48 CHEMBIO DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2022)
             13.1.10 EKF DIAGNOSTICS HOLDINGS PLC
                        TABLE 181 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY OVERVIEW
                        FIGURE 49 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2022)
             13.1.11 TRINITY BIOTECH PLC
                        TABLE 182 TRINITY BIOTECH PLC: COMPANY OVERVIEW
                        FIGURE 50 TRINITY BIOTECH PLC: COMPANY SNAPSHOT (2022)
             13.1.12 WERFEN, S.A.
                        TABLE 183 WERFEN: COMPANY OVERVIEW
                        FIGURE 51 WERFEN, S.A.: COMPANY SNAPSHOT (2022)
             13.1.13 NOVA BIOMEDICAL
                        TABLE 184 NOVA BIOMEDICAL: COMPANY OVERVIEW
             13.1.14 PTS DIAGNOSTICS
                        TABLE 185 PTS DIAGNOSTICS: COMPANY OVERVIEW
             13.1.15 SEKISUI DIAGNOSTICS
                        TABLE 186 SEKISUI DIAGNOSTICS: COMPANY OVERVIEW
             13.1.16 EUROLYSER DIAGNOSTICA GMBH
                        TABLE 187 EUROLYSER DIAGNOSTICA GMBH: COMPANY OVERVIEW
             13.1.17 RESPONSE BIOMEDICAL
                        TABLE 188 RESPONSE BIOMEDICAL: COMPANY OVERVIEW
             13.1.18 ALFA SCIENTIFIC DESIGNS, INC.
                        TABLE 189 ALFA SCIENTIFIC DESIGNS, INC: COMPANY OVERVIEW
             13.1.19 BODITECH MED INC.
                        TABLE 190 BODITECH MED INC.: COMPANY OVERVIEW
             13.1.20 BTNX INC.
                        TABLE 191 BTNX INC.: COMPANY OVERVIEW
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
     13.2 OTHER PLAYERS 
             13.2.1 LIFESCAN IP HOLDINGS, LLC
             13.2.2 ASCENSIA DIABETES CARE HOLDINGS AG
             13.2.3 FLUXERGY
             13.2.4 PRECISION BIOSENSOR, INC.
             13.2.5 ACON LABORATORIES, INC.
             13.2.6 A. MENARINI DIAGNOSTICS S.R.L.
             13.2.7 ORASURE TECHNOLOGIES, INC.
             13.2.8 MANKIND PHARMA
             13.2.9 GRIFOLS, S.A.
             13.2.10 DIASORIN S.P.A.
 
14 APPENDIX (Page No. - 314)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATION OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS 

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, fundamental market dynamics, and key player strategies.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the point of care diagnostics market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the point of care diagnostics market. The primary sources from the demand side include hospitals, clinical laboratories, pharmacies, ecommerce platforms, physician’s office, among others. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.

A breakdown of the primary respondents is provided below:

*Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note: Companies are classified into tiers based on their total revenue. As of 2022, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion.

Point-of-Care Diagnostics Market Size, and Share

*C-level primaries include CEOs, CFOs, COOs, and VPs.

**Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note: Companies are classified into tiers based on their total revenue; as of 2021, Tier 1 = >USD 10 billion, Tier 2 = USD 1 billion to USD 10 billion, and Tier 3 = <USD 1 billion.

Source: MarketsandMarkets Analysis

To know about the assumptions considered for the study, download the pdf brochure

Market Estimation Methodology:

For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the global point of care diagnostics market. All the major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/sub-segments was done for the major players (who contribute at least 85–90% of the market share at the global level). Also, the global point of care diagnostics market was split into various segments and sub-segments based on:

  • list of major players operating in the point-of-care market at the regional and/or country level
  • Product mapping of various manufacturers for point-of-care diagnostics products at the regional and/or country level
  • Mapping of annual revenue generated by listed major players from point-of-care diagnostics segments (or the nearest reported business unit/product category)
  • Revenue mapping of major players to cover at least 65–75% of the global market share as of 2022
  • Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments
  • Summation of the market value of all segments/subsegments to arrive at the global point-of-care  diagnostics market

The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

Point-of-Care Diagnostics Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Data Triangulation:

After deriving the overall Point of care diagnostics  market value data from the market size estimation process, the total market value data was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all the segments, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by studying various qualitative and quantitative variables as well as by analyzing regional trends for both the demand- and supply-side macro indicators.

Market Definition:

Point of care testing includes  conducting diagnostic tests near the patient, offering  immediate results enabling helathacare providers to expedite the clinical decisions. Point of care devices are best suited for  various healthcare settings, including clinical laboratories , hospitals, physician offices, ambulances, and at  homes, emergency rooms

Key Market Stakeholders:

  • Point-of-care Diagnostic Product Manufacturers
  • Distributors, Channel Partners, and Third-party Suppliers
  • Clinical Laboratories, Reference Laboratories, and Contract Testing Laboratories
  • Hospitals, Diagnostic Clinics, and Sports/Military Facilities
  • Contract Manufacturing Organizations (CMOs)
  • Contract Research Organizations (CROs)
  • R&D Companies
  • Business Research and Consulting Service Providers
  • Medical Research Laboratories
  • Academic Medical Centers, Universities, and Hospitals

Report Objectives:

  • To define, describe, and forecast the point-of-care diagnostics  market by Product, Platform, Mode of Purchase, Sample, End User, and Region
  • To provide detailed information about major factors influencing market growth (key drivers, restraints, opportunities, and industry-specific challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and their contributions to the overall point-of-care and rapid diagnostics   market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the market value of various segments and sub-segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players active in the point of care diagnostics market and comprehensively analyze their global revenue shares and core competencies
  • To track and analyze competitive market-specific developments such as product approvals & commercialization, agreements, partnerships, collaborations, acquisitions, and expansions in the point-of-care diagnostics   market

Available Customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the present global point of care diagnostics  market report:

Product Analysis:

  • Product matrix, which gives a detailed comparison of the product portfolios of the top fifteen companies

Company Information:

  • Detailed analysis and profiling of additional market players (up to 15)

Geographic Analysis:

  • Further breakdown of the Rest of Europe's point of care diagnostics  market into Russia, Belgium, the Netherlands, Switzerland, Austria, Finland, Sweden, Poland, and Portugal, among other
  • Further breakdown of the Rest of Asia Pacific point of care diagnostics  market into Singapore, Taiwan, New Zealand, Philippines, Malaysia, and other APAC countries.
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 2702
Published ON
Feb, 2024
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Point of Care Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback